近期论文

查看导师新发文章 （温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

[1] Zhou SG, Zhou SF ,Huang HQ, Chen JW, Huang M, Liu PQ (Corresponding author). Proteomic Analysis of Hypertension-Induced Left Ventricular Hypertrophy by Two-Dimensional Difference Gel Electrophoresis and Mass Spectrometry. J Proteome Res, 2006, 5(11):2901-2908. SCI, IF: 6.919. [2] Xu S, Ogura S, Chen J, Little PJ, Moss J, Liu P (Corresponding author). LOX-1 in atherosclerosis:biological functions and pharmacological modifiers. Cell Mol Life Sci. 2012 Nov3. [Epub ahead of print] PubMed PMID: 23124189. SCI, IF: 6.570. [3] Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ (Corresponding author) Shen XY, Ji Y. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-kappaB-dependent transcriptional activity, Br J Pharmacol, Br J Pharmacol. 2013 Jan;168(1):117-28. SCI, IF: 4.925. [4] Chen Y, Wang Y, Chen J, Chen X, Cao W, Chen S, Xu S, Huang H, Liu PQ (Corresponding author). Roles of transcriptional corepressor RIP140 and coactivator PGC-1α in energy state of chronically infarcted rat hearts and mitochondrial function of cardiomyocytes, Mol Cell Endocrinol. 2012 Oct 15;362(1-2):11-8 SCI, IF: 4.119. [5] Gao S, Liu Z, Li H, Little PJ, Liu PQ (Corresponding author), Xu S. Cardiovascular actions and therapeutic potential of tanshinone IIA, Atherosclerosis, 2012, 220: 3-10. SCI, IF: 4.086. [6] Cai Y, Yu SS, Chen SR, Pi RB, Gao S, Li H, Ye JT, Liu PQ (Corresponding author). Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett. 2012 Mar 23;586(6):866-74. SCI, IF: 3.538. [7] Wang P, Zhou S, Xu L, Lu Y, Yuan X, Zhang H, Li R, Fang J, Liu P Liu PQ (Corresponding author). Hydrogen peroxide-mediated oxidative stress and collagen synthesis in cardiac fibroblasts: Blockade by tanshinone IIA. J Ethnopharmacol. 2013 Jan 9;145(1):152-61 (IF: 3.728) [8] Cai Y, Yu SS, Chen TT, Gao S, Geng B, Yu Y, Ye JT, Liu PQ (Corresponding author). EGCG inhibits CTGF expression via blocking NF-κB activation in cardiac fibroblast. Phytomedicine. 2012. 20(2):106-13. SCI, IF: 3.300. [9] Le K, Li R, Xu S, Wu X, Huang H, Bao Y, Cai Y, Lan T, Moss J, Li C, Zou J, Shen X, Liu PQ (Corresponding author). PPARalpha activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4, Arch Biochem Biophys, 2012, 518: 71-78. SCI, IF:3.022. [10] Xu S, Liu Z, Huang Y, Le K, Tang F, Huang H, Ogura S, Little PJ, Shen X, Liu PQ (Corresponding author). Tanshinone II-A inhibits oxidized LDL-induced LOX-1 expression in macrophages by reducing intracellular superoxide radical generation and NF-κB activation, Transl Res, 2012. Online published. SCI, IF: 2.903. [11] Mei Z, Yan P, Situ B, Mou Y, Liu PQ (Corresponding author). Cryptotanshinione Inhibits beta-Amyloid Aggregation and Protects Damage from beta-Amyloid in SH-SY5Y Cells, Neurochem Res, 2012, 37: 622-628. SCI, IF: 2.608. [12] Chen W, Tang F, Xie B, Chen S, Huang H, Liu PQ (Corresponding author). Amelioration of atherosclerosis by tanshinone IIA in hyperlipidemic rabbits through attenuation of oxidative stress, Eur J Pharmacol, 2012, 674: 359-364. SCI, IF: 2.737. [13] Tang W, Wei Y, Le K, Li Z, Bao Y, Gao J, Zhang F, Cheng S, Liu P (Corresponding author). Mitogen-activated protein kinases ERK 1/2- and p38-GATA4 pathways mediate the Ang II-induced activation of FGF2 gene in neonatal rat cardiomyocytes. Biochemical Pharmacology 2011. 81: 518-525. SCI, IF: 4.899. [14] Wang CZ, Zhang Y, Li XD, Hu Y, Fang ZG, Lin DJ, Xiao RZ, Huang RW, Huang HQ, Liu PQ (Corresponding author), Liu JJ. PPARγ agonist suppresses TLR4 expression and TNF-α production in LPS stimulated monocyte leukemia cells. Cell Biochem Biophys. Cell Biochem Biophys. 2011;60(3):167-72. SCI, IF: 4.312. [15] Xu S, Little PJ, Lan T, Huang Y, Le K, Wu X, Shen X, Huang H, Cai Y, Tang F, Wang H, Liu PQ (Corresponding author). Tanshinone II-A attenuates and stabilizes atherosclerotic plaques in apolipoprotein-E knockout mice fed a high cholesterol diet, Arch Biochem Biophys, 2011, 515: 72-79. SCI, IF: 3.022. [16] Xu S, Liu PQ (Corresponding author). Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013 Feb;23(2):149-53 IF: 3.57 [17] Geng B, Cai Y, Gao S, Lu J, Zhang L, Zou J, Liu M, Yu S, Ye J, Liu PQ (Corresponding author). PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.Biochem Biophys Res Commun. 2013 Jan 18;430(3):944-50 IF:2.52 [18] Tang FT, Cao Y, Wang TQ, Wang LJ, Guo J, Zhou XS, Xu SW, Liu WH, Liu PQ (Corresponding author), Huang HQ. Tanshinone IIA attenuates atherosclerosis in ApoE(-/-) mice through down-regulation of scavenger receptor expression. Eur J Pharmacol. 2011 ;650(1):275-84. SCI, IF: 2.737. [19] Tang S, Shen XY, Huang HQ, Xu SW, Yu Y, Zhou CH, Chen SR, Le K, Wang YH, Liu PQ (Corresponding author). Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways, Inflammation, 2011, 34: 111-118. [20] Wang P, Wu X, Bao Y, Fang J, Zhou S, Gao J, Pi R, Mou YG, Liu PQ (Corresponding author). Tanshinone IIA prevents cardiac remodeling through attenuating NAD(P)H oxidase-derived reactive oxygen species production in hypertensive rats, Pharmazie, 2011, 66: 517-524.